Zebra Medical Vision Raises $30M, Unveils the Broadest, Automated AI Based Radiology Chest X-Ray Reader to Date
Zebra Medical Vision (https://www.zebra-med.com/), the leading machine and deep learning startup, is announcing today it has raised $30M in C round funding, bringing the total investment in the company to $50M. In addition, the company is unveiling its Textray chest x-ray research (https://arxiv.org/abs/1806.02121) today, the most comprehensive AI research conducted on chest x-rays to date, which provides a glimpse into a future automated chest x-ray analysis product being developed by the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180607005546/en/
Zebra Medical Vision Raises $30M, unveils the broadest, automated AI based Radiology Chest X-Ray reader to date (Photo: Zebra-Med)
This round of investment is led by aMoon Ventures with the participation of strategic healthcare investors Aurum, Johnson & Johnson Innovation JJDC Inc. and Intermountain Healthcare and leading global AI scientists Professor Fei Fei Lee and Richard Socher. These new investors are joining a list of existing investors Khosla Ventures, NVIDIA, Marc Benioff, OurCrowd and Dolby Ventures who also participated in this C round.
The chest x-ray AI analytics product was trained using nearly 2 million images to identify 40 different common clinical findings. The results of the study establish a new bar for AI research in medical imaging, demonstrating high rates of agreement between the algorithm and human radiologist experts. This publication continues Zebra-Med’s mission to drive a higher standard of care across the radiology domain and collaborate with the medical community to improve patient care.
Zebra Medical Vision is a leader in the growing market of AI-based tools for radiology. The company has received the CE regulatory mark for seven of its products, as well as approvals in numerous countries across Latin America and Asia, and continues to build a strong pipeline of AI based products. It’s most recent announcements were the CE approval of CT brain bleed and mammography lesion detection algorithms. On its path to build the world’s most comprehensive visual lab, the company’s current and future arsenal of AI algorithms is bundled into a unique $1 per scan offering to hospitals, in order to meet the company founders’ vision toward scalable, transparent and affordable care globally.
“Medical experts worldwide are facing a critical challenge in handling overwhelming demand. We are excited to partner with the Zebra-Med team, which is harnessing the power of data and machine learning to provide physicians and healthcare systems with tools to dramatically increase capacity, while improving patient care," said Dr. Yair Schindel MD, Managing Partner at aMoon VC. “This investment aligns with our vision of backing scalable and sustainable innovations that will have a valuable impact on fundamental facets of global healthcare.”
“I am pleased to partner with Zebra Medical Visions’ distinguished panel of investors,” added Morris Kahn, founder and owner of Aurum Ventures. “I am a big believer in AI based healthcare solutions and Zebra Medical Vision's technologies will play a major role in improving the capacity and quality of treatment for patients all over the world.”
“I’m extremely proud of our team here at Zebra Medical Vision, that is pushing to develop and release next generation AI products with the commitment to make them affordable to the global market,” said Elad Benjamin, co-founder and CEO of Zebra Medical Vision.
Read more on Zebra Medical Vision’s X-ray research: https://zebramedblog.wordpress.com/2018/06/06/textray-mining-clinical-reports-to-gain-a-broad-understanding-of-chest-x-rays/
About Zebra Medical Vision:
Zebra Medical Vision uses deep learning to create and provide next generation products and services to the healthcare industry. Its Imaging Analytics Platform gives healthcare institutions tools to potentially identify patients at risk of disease, allowing them to improve patient care. Headquartered in Kibbutz Shefayim Israel, the Company was founded in 2014 by Co-Founders Eyal Toledano, Eyal Gura, and Elad Benjamin and funded by Khosla Ventures, Marc Benioff, Intermountain Investment Fund, OurCrowd and Dolby Ventures. For more information visit https://www.zebra-med.com/.
aMoon is a leading Israeli life sciences venture fund which invests globally in disruptive healthcare ventures. The aMoon team is passionate about building successful businesses and helping Israeli digital health, biopharma and medical technology companies realize their potential.
aMoon partners with management teams dedicated to accelerating cures for the world's most life-threatening conditions and those providing solutions for global healthcare's biggest cost drivers. For more information, visit https://amoon.fund/.
Company Media Contact:
Blonde 2.0 for Zebra Medical Vision
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)21.9.2018 22:13 | Pressemelding
Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced
Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 17:43 | Pressemelding
BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar
Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41 | Pressemelding
Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo
Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46 | Pressemelding
The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+
Asda Selects HCL Technologies to Help Drive IT Transformation21.9.2018 12:16 | Pressemelding
HCL Technologies (HCL), a leading global technology company, today announced that it has been selected to help drive IT transformation at the UK’s third-largest grocery retailer, Asda. The three-year application services contract will see HCL transform Asda’s IT Application Services with a new DevOps delivery model to drive data and analytics and support back-office applications through the full lifecycle of development, testing and support. HCL will also build a central data management platform to enable Asda to improve its insight and analytics capabilities. Asda operates more than 600 stores across the UK, employing over 135,000 people. Asda wanted to adopt a more agile approach towards application development and testing. This would allow the company to respond faster to business requirements and reduce time to market, while driving better user experience and satisfaction. HCL was selected due to its extensive expertise in successfully delivering similar large scale IT transformati